SHATTUCK LABS INC. - COMMON STOCK

Shattuck Labs Announces Participation in Upcoming Leerink Partners Therapeutics Forum: I&I and Metabolism

02 Jul 2025 04:00:00 By Nasdaq GlobeNewswire

Shattuck Labs Reports First Quarter 2025 Financial Results and Recent Business Highlights

01 May 2025 13:20:00 By Nasdaq GlobeNewswire

Shattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare Conference

02 Apr 2025 14:00:00 By Nasdaq GlobeNewswire

Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights

27 Mar 2025 04:00:00 By Nasdaq GlobeNewswire

Shattuck Labs Announces Positive Data from the Preclinical GLP Toxicology Study of SL-325 at the 20th Congress of European Crohn’s and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025

20 Feb 2025 06:00:00 By Nasdaq GlobeNewswire

Shattuck Labs Announces Oral Presentation at Upcoming 20th Congress of European Crohn’s and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025

13 Feb 2025 13:30:00 By Nasdaq GlobeNewswire

Shattuck Labs Announces Poster Presentation at Upcoming 2025 Crohn’s and Colitis Congress

04 Feb 2025 04:00:00 By Nasdaq GlobeNewswire

Shattuck Labs Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

06 Jan 2025 13:59:31 By Nasdaq GlobeNewswire

Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2025

02 Jan 2025 04:00:00 By Nasdaq GlobeNewswire

Shattuck Labs Announces Participation in Upcoming December Conferences

25 Nov 2024 04:00:00 By Nasdaq GlobeNewswire

Shattuck Labs Reports Third Quarter 2024 Financial Results and Recent Business Highlights

14 Nov 2024 04:00:01 By Nasdaq GlobeNewswire

Shattuck Labs Provides Company Update and Announces SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Targeting the TL1A/DR3 Signaling Pathway

01 Oct 2024 03:30:00 By Nasdaq GlobeNewswire

Shattuck Labs Reports Second Quarter 2024 Financial Results and Recent Business Highlights

01 Aug 2024 13:05:00 By Nasdaq GlobeNewswire

Shattuck Labs Announces Participation in Upcoming BTIG Virtual Biotechnology Conference

30 Jul 2024 14:00:00 By Nasdaq GlobeNewswire

Shattuck Labs Announces Addition to Russell 2000® and Russell 3000® Indexes

01 Jul 2024 03:00:00 By Nasdaq GlobeNewswire

Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients

14 Jun 2024 03:00:00 By Nasdaq GlobeNewswire

Shattuck Labs Announces Orphan Drug Designation Granted by the U.S. Food and Drug Administration (FDA) for SL-172154 for the Treatment of Acute Myeloid Leukemia (AML)

10 Jun 2024 04:30:00 By Nasdaq GlobeNewswire

Shattuck Labs to Host Investor Call and Webcast on Additional Interim Data Presented at the European Hematology Association (EHA) 2024 Congress from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients

06 Jun 2024 04:30:00 By Nasdaq GlobeNewswire

Shattuck Labs to Present Additional Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients at the European Hematology Association (EHA) 2024 Congress

14 May 2024 13:15:00 By Nasdaq GlobeNewswire

Shattuck Labs Reports First Quarter 2024 Financial Results and Recent Business Highlights

02 May 2024 04:05:00 By Nasdaq GlobeNewswire